Global Brain Tumor Drugs Market Size Study & Forecast, by Therapy (Targeted Therapy, Chemotherapy, Immunotherapy, Others), by Indication (Pituitary, Meningioma, Glioma, Others), by Distribution Channel (Hospital Pharmacy, Retail & Online Pharmacy) and Reg

Global Brain Tumor Drugs Market Size Study & Forecast, by Therapy (Targeted Therapy, Chemotherapy, Immunotherapy, Others), by Indication (Pituitary, Meningioma, Glioma, Others), by Distribution Channel (Hospital Pharmacy, Retail & Online Pharmacy) and Regional Analysis, 2023-2030

Global Brain Tumor Drugs Market is valued at approximately USD 1.80 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 10.2% over the forecast period 2023-2030. Brain tumors are abnormal growths of cells that develop in the brain or nearby areas. Tumors that develop in the brain is the primary brain tumor and tumor that begin in other parts of the body is known as secondary or metastatic brain tumors. The size of the tumor varies from very small size to large size. The increasing prevalence of brain tumors is a major contributing factor to the growth of the market. However, the high cost of treatments hinder market expansion.

The rising prevalence of brain cancer due to changing lifestyle habits, rapid urbanization, and increasing rate of active smokers is driving the market growth. According to Globocan 2020 estimates, there were 308,102 new cases of brain cancer worldwide in 2021, resulting in 251,329 new deaths. According to the American Cancer Society, around 24,530 malignant brain or spinal cord tumors were diagnosed in 2021, with an additional 3,460 children under the age of 15 expected to be diagnosed with brain or CNS tumors this year. The European Society for Medical Oncology (ESMO) has adopted a neurosurgery protocol to slow down tumor progression and provide a longer survival time, according to a research study titled ""Brain Tumor Management Amidst COVID-19 Pandemic"" in August 2020. The growing concern for the disease and its treatment is driving the market, along with key players investing in research and development. Furthermore, increasing government initiatives to provide a conducive environment for drug approval and the rising number of pharmaceutical companies developing these drugs propel the market growth. However, the side effects associated with these drugs hinder market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Brain Tumor Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 due to proper reimbursement policies in the U.S. and the increasing launch of new drugs. Asia Pacific is expected to grow significantly over the forecast period, due to varying regulatory policies and rising awareness about cancer and its types. According to the Brain Tumor Research Organization, Australia has average rating of brain tumor care was the lowest of all cancers, with a score of 8.37 out of 10.

Major market player included in this report are:
Johnson & Johnson Services, Inc.
Bayer AG
F. Hoffmann-La Roche Ltd
Eisai Co. Ltd
Novartis AG
Merck & Co. Inc.
Amgen Inc.
AstraZeneca PLC,
Pfizer, Inc.
GlaxoSmithKline PLC

Recent Developments in the Market:
 In November 2021, Pfizer Inc. acquired Trillium Therapeutics, a clinical-stage immuno-oncology company that focuses primarily on developing innovative therapies for the treatment of cancer.
 In September 2022, F. Hoffmann-La Roche Ltd. acquired Good Therapeutics, to gain rights to Good Therapeutics' platform technology, which has applications in various fields such as autoimmune diseases, pain management, metabolic diseases, and cancer.

Global Brain Tumor Drugs Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Therapy, Indication, Distribution Channel, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Therapy:
Targeted Therapy
Chemotherapy
Immunotherapy
Others

By Indication:
Pituitary
Meningioma
Glioma
Others

By Distribution Channel:
Hospital Pharmacy
Retail & Online Pharmacy

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Johnson & Johnson Services, Inc.
Bayer AG
F. Hoffmann-La Roche Ltd
Eisai Co. Ltd
Novartis AG
Merck & Co. Inc.
Amgen Inc.
AstraZeneca PLC,
Pfizer, Inc.
GlaxoSmithKline PLC

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.